

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 August 2023 (10.08.2023)



(10) International Publication Number
WO 2023/150758 A1

(51) International Patent Classification:

A61K 9/51 (2006.01) *A61K 39/39* (2006.01)
A61K 31/685 (2006.01) *A61P 31/00* (2006.01)
A61K 31/4745 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2023/062064

(22) International Filing Date:

06 February 2023 (06.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/307,569 07 February 2022 (07.02.2022) US
63/417,282 18 October 2022 (18.10.2022) US

(71) Applicant: **CORNER THERAPEUTICS, INC.** [US/US];
300 North Beacon Street, Building 39, Suite 202, Water-
town, Massachusetts 02472 (US).

(72) Inventors: **GOSSELIN, Emily A.**; c/o Corner Thera-
peutics, Inc., 300 North Beacon Street, Building 39, Suite 202,
Watertown, Massachusetts 02472 (US). **CORNFORTH,**
Andrew N.; c/o Corner Therapeutics, Inc., 300 North Bea-
con Street, Building 39, Suite 202, Watertown, Massachu-
setts 02472 (US). **CHOW, Jonathan**; c/o Corner Thera-
peutics, Inc., 300 North Beacon Street, Building 39, Suite
202, Watertown, Massachusetts 02472 (US). **ZHIVAKI,**
Dania; c/o Corner Therapeutics, Inc., 300 North Beacon
Street, Building 39, Suite 202, Watertown, Massachusetts
02472 (US). **FINN, Kelsey K.**; c/o Corner Therapeutics,
Inc., 300 North Beacon Street, Building 39, Suite 202, Wa-
tertown, Massachusetts 02472 (US).

(74) Agent: **LEKUTIS, Christine** et al.; Morrison & Foerster
LLP, 425 Market Street, San Francisco, California 94105
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.


(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: HYPERACTIVATING LIPID NANOPARTICLES

FIG. 8D



(57) Abstract: The present disclosure relates to lipid nanopar-
ticles comprising a lysophosphatidylcholine (LPC) compound and
at least one further lipid, and uses thereof in hyperactivating mam-
malian dendritic cells, such as human dendritic cells. The present
disclosure also relates to compositions comprising lipid nanopar-
ticles comprising a LPC and at least one further lipid, in which the
compositions comprise one or more of a pathogen recognition re-
ceptor agonist, an antigen, and mammalian dendritic cells, as well
as methods for production and use of the compositions.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*